AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...

AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...

Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...

AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen ...

AstraZeneca announced on Monday that Imfinzi, or durvalumab, has been recommended for approval in the European Union for ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...

AstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the ...

Imfinzi in combination with chemotherapy has been recommended for approval in the European Union for the treatment of ...

Imfinzi plus chemotherapy significantly improved event-free survival in resectable Stage II-IVA gastric and GEJ cancer patients. A strong trend in overall survival benefit was observed, with final ...